Roche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a significant number of patients with triple-negative breast cancer, a development hailed by doctors as a promising advance in fighting the aggressive disease.
from Reuters: Health https://ift.tt/2SOE5eA
via IFTTT
0 comments: